Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.67 |
| ▸ | HTR2C | P28335 | 7/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28317600 | 0.89 | SLC6A2 (0.55) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL2046629 | 0.88 | HTR1A (0.50) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL15912627 | 0.85 | ALOX5AP (0.51) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15226931 | 0.84 | SLC6A2 (0.51) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL6925353 | 0.83 | SLC6A2 (0.69) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL5584542 | 0.82 | HTR2C (0.73) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL27812820 | 0.82 | HTR2C (0.58) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL19703133 | 0.81 | HTR2C (0.57) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL2781463 | 0.80 | HTR2C (0.65) | HTR1ASLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL10819363 | 0.79 | GRM2 (0.47) | HTR1ASLC6A2SLC6A4SLC6A3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737533-B2 | 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders | Janssen Pharmaceuticals. Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2012062752-A1 | RADIOLABELLED mGLuR2 PET LIGANDS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
| CN-1223650-A | Piperidines and pyrrolidines | MERCK PATENT GMBH (DE) | 1999-07-21 | — | — | CN | disclosed |
| EP-0898569-A1 | PIPERIDINES AND PYRROLIDINES | MERCK PATENT GmbH (DE) | 1999-03-03 | — | — | EP | disclosed |
| WO-1997040038-A1 | PIPERIDINES AND PYRROLIDINES | MERCK PATENT GMBH (DE) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230459-A1 | RADIOLABELLED mGluR2 PET LIGANDS | GRM2, GRM3, GRM1 | HTR1A 702/4885SLC6A2 182/4885SLC6A4 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.